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Abstract
Background: The objective of this study is to evaluate current literature on the association between cognitive
dysfunction and nocturia.
Methods: A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement was conducted through MEDLINE, EMBASE and COCHRANE databases and completed in
November 2019. Randomized and non-randomized studies were included if they assessed the association between
cognitive dysfunction and nocturia in older participants with or without neurological diseases. The quality of
included studies was evaluated using the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS).
Results: A total of 8 cross-sectional studies conducted in older patient populations met the criteria for inclusion. A
statistically significant association was identified in 6 studies on univariate analysis, which persisted in 2 studies after
controlling for confounding factors. The association between cognitive dysfunction and nocturia was positive for all
6 significant analyses. The overall risk of bias was unclear.
Conclusion: A significant positive association between cognitive dysfunction and nocturia was identified. However,
research has been limited to cross-sectional studies, which precludes identification of causality between cognitive
dysfunction and nocturia. Heightened awareness of the complex interplay between cognition and nocturia would
allow professionals involved in the care of cognitively impaired patients with concomitant nocturia to more
effectively manage these symptoms.
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Background
Nocturia, defined as the act of waking to void during the
hours of intended sleep, is among the most common
and bothersome lower urinary tract symptoms (LUTS)
[1, 2]. Although nocturia is a pervasive complaint across
different patient populations, older people are dispropor-
tionally affected, with clinically-significant symptoms re-
ported in up to 60% of patients over 70 years of age [3].
Nocturia has been associated with significant morbidity
and mortality [4] and shown to have a direct adverse ef-
fect on sleep architecture [5, 6]. Among older patient
populations, nocturia confers an increased risk of both
falls and hip fractures [7, 8], and it stands to reason that
this effect may be more pronounced in the setting of
concomitant cognitive impairment [9].
Notably, there exists a robust association between cog-
nitive dysfunction - which refers to deficits in attention,
verbal and nonverbal learning, short-term and working
memory, visual and auditory processing, problem solv-
ing, processing speed, motor functioning - and other
LUTS, particularly urinary incontinence [10–12]. More-
over, current literature has identified a diverse array of
risk factors common to both nocturia and cognitive dys-
function, including aging, comorbidities [13], brain le-
sions - particularly those affecting the hypothalamic-
pituitary axis [14], and sleep disturbances [15]. However,
relative to other LUTS, the relationship between noc-
turia and cognitive dysfunction remains poorly charac-
terized. Increased awareness of the complex interplay
between cognition and nocturia would facilitate the
evaluation and management of cognitively impaired pa-
tients with concomitant nocturia.
The objective of this systematic review was to evaluate
available evidence on the association between cognitive
dysfunction and nocturia.
Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [16].
Eligibility criteria
Types of studies
Original studies including randomized controlled trials
(RCTs), non-RCTs, single-arm cohort studies, case-
control studies, cross-sectional studies, and case series
were included. Review articles and meta-analyses were
not included, but references from these studies were
reviewed, and eligible articles were subsequently
retrieved.
Population
Only studies involving adults were selected. No limits on
gender, ethnicity or setting were applied. The presence
of nocturia had to have been reported in participants, re-
gardless of the method of assessment or the threshold
used to define nocturia. Cognitive dysfunction had to
have been assessed by either a validated neuropsycho-
logical test or defined via formal diagnosis of a neuro-
cognitive disorder.
Outcomes
The primary outcome was the association between cog-
nitive dysfunction with neurodegenerative disorders of
aging and nocturia. Measurement of this association was
specified by an effect size indicator and/or a statistical
significance level.
Search strategy and information sources
The MEDLINE, EMBASE, COCHRANE and CENTRAL
databases were used with specific keywords (MeSH or
Emtree terms) combined with Boolean operators. The
complete search strategy is available as supplementary
data (Additional File 1). The search was completed in
November 2019 and no date limits were applied. No
limit of language was applied. References cited in sys-
tematic reviews or meta-analyses were searched. Once
key articles were identified, additional searches were per-
formed on PubMed using the “Related Articles” search
feature.
Data collection and analysis
Study selection
Two review authors (RH & TM) independently screened
the titles and abstracts yielded by the search after inclu-
sion criteria had been applied. Full articles were obtained
for all titles that appeared to meet the inclusion criteria
or for which there was any uncertainty. Review authors
then screened the complete articles and independently
determined whether these met the inclusion criteria.
Disagreement was resolved through discussion. Ration-
ale for excluding trials was recorded. Figure 1 summa-
rizes this selection process according to the PRISMA
statement.
Data extraction
Duplicate data were extracted independently (RH &
TM) using a standard spreadsheet, which captured infor-
mation on study design, population, and the association
between cognitive dysfunction and nocturia. A summary
is provided in the results section (Tables 1 & 2).
Assessment of the risk of bias in individual studies
The quality of non-randomized studies was assessed
using the validated Risk of Bias Assessment tool for
Non-randomized Studies (RoBANS) [24]. Dispositions
were made independently by two authors (RH & TM).
Disagreements were resolved first by discussion, and
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then by consulting a third author for arbitration as war-




A flowchart of the database search and selection process
is provided in Fig. 1. Of the 1023 non-duplicate articles
identified from the databases, 64 articles were eligible
for systematic review. A total of 8 studies were included
in the final analysis.
Study characteristics
Study characteristics are summarized in Table 1. The 8
studies included all featured a cross-sectional study de-
sign and community-dwelling participants. Four studies
specifically enrolled older patients [17, 21–23], 3 studies
[18–20] were conducted in Parkinson’s disease (PD) pa-
tients and 1 enrolled participants with probable Alzhei-
mer’s disease (AD) [11]. Cognitive dysfunction was
assessed by Mini-Mental State Examination (MMSE) in
6 studies [11, 17, 20–23], and also the Clinical Dementia
Rating (CDR) scale in 1of these studies [11]. The Mon-
treal Cognitive Assessment was used in 1 study [18], and
a specific validated scale for impulsivity in PD in 1 study
[19]. The prevalence of cognitive dysfunction ranged
from 4 to 58% in the studies which reported this param-
eter [17, 18, 23]. Nocturia was defined as self-reported
awakening from sleep to pass urine 2 or more times per
night [21–23], or without any definite threshold [11, 17]
or by symptom questionnaires [18–20]. Overall, nocturia
was reported in 19 to 61% of study participants [17, 20].
Assessment of the association between cognitive
dysfunction and nocturia
The association between cognitive dysfunction and nocturia
was statistically significant in 6 studies [11, 17, 18, 21–23],
all in the same direction (Table 2). In 1 study [18], nocturia
was more frequently identified in PD patients with cogni-
tive dysfunction compared to those without (56% vs. 37%
respectively). In 4 other studies [17, 21–23], a higher
MMSE score was a protective factor for nocturia, whereas
Jung et al. (2017) did not find any correlation between
MMSE score and nocturia in patients with probable AD.
Lee et al. (2012) determined that a higher MMSE score was
an independent protective factor after adjustment for mul-
tiple potential confounders (OR 0.6, 95% CI [0.5–0.9], p =
0.006). In the study by Zhang et al. (2016), this association
was independent in multivariable analysis (OR 1.7, 95%CI
[1.1–2.8], p = 0.03), but it should be noted that the group
Fig. 1 Flow diagram
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studied the entire urinary domain (including nocturia) of
the Non-Motor Symptoms Scale (opposed to nocturia as a
standalone entity). Minimal clinically important difference
in cognitive scores was reached in two of the three studies
where assessment was possible [17, 22].
Risk of bias in included studies
The risk of biases is summarized in Fig. 2. Regarding the
selection of participants, the risk of bias was unclear in
all studies, since no criteria could be applied to cross
sectional studies using the RoBANS instrument. Never-
theless, 3 studies [21–23] randomly selected their partic-
ipants, with a response rate ranging from 75 to 98%. Of
the 8 studies included, only 3 controlled their analyses
for confounding factors [18, 22, 23]. Potential confound-
ing factors considered included age (in all of these stud-
ies), ethnicity [23], gender [18], education (in all of these
studies), PD history (age of onset, disease severity
assessed by the Unified PD Rating Scale, hallucination or
gastrointestinal symptoms) in the study by Zhang et al.
(2016), urological history (transitional volume zone, his-
tory of benign prostate hyperplasia, alpha blockers in-
take) in the study by Lee et al. (2012) and comorbidities
such as sleep or fatigue symptoms [18], lower limbs
edema, hypertension, obesity or urinary incontinence
[23], depression [18, 22] and anxiety [18]. When gender
was not considered, analyses were stratified according to
it. All but 1 of the studies [23] were deemed to be at low
Table 1 Study characteristics
Study Population Nocturia Assessment Cognitive dysfunction Assessment
Dutoglu et al. (2019) [17] 858 outpatients admitted to a
geriatric center
Female: 100%
Mean (sd) age: 74.1 (8.2) years
“Generally, during the past
30 days, how many times do you
usually urinate after you have gone
to sleep at night until the time you
got up in the morning?”
Cut-off: 1, 2, 3, 4 or more
Prevalence: 19.0, 24.2, 18.4, and 24.1%
respectively
MMSE and Dementia diagnosed
using the DSM V
Mean (sd) MMSE score: 24.7 (4.9),
25.0 (4.2), 24.9 (3.7), 24.2 (4.4), 23.9 (4.9)
in patients with 0, 1, 2, 3 or ≥ 4 nocturia
episodes respectively
Prevalence (dementia): 4.4%
Jung et al. (2017) [11] 376 patients with probable
Alzheimer’s disease
Female: 51.1%
Age range: 56–92 years
OABSS
Mean (sd) number of nocturia episodes:
1.2 (0.8), 1.2 (0.9) and 1.6 (1.0) in patients
with OABSS ≤5, 6–11 or ≥ 12 respectively
Prevalence: NR
MMSE and CDR scale
Mean (sd) MMSE score: 14.4 (7.6) in
patients with OAB
Mean (sd) CDR score: 2.3 (0.9) in
patients with OAB
Zhang et al. (2016) [18] 454 patients with Parkinson’s
disease
Female: 42.7%
Mean (sd) age: 61.5 (10.9) years
NMSS





Mean (sd) MoCA score: 23.7 (4.5)
Prevalence (MoCA ≤25): 58.1%
Scullin et al. (2013) [19] 143 patients with Parkinson’s
disease
Female: 35%
Mean (sd) age: 64.7 (9.0) years
“When you awaken during the night,
how often do you urinate?” on sleep
questionnaire drawn from existing
studies; Nocturia frequency evaluated
on 4-point Likert scale (1 = “never,”
4 = “very often”)
Prevalence: NR
Impulsivity determined by at least 1
“yes” to the Minnesota Impulse Disorder
Interview (MIDI) questions
Prevalence: 26.6%
Vaughan et al. (2013) [20] 63 patients with Parkinson’s
disease
Female: 35%





Mean (sd) MMSE score: 28.6 (1.5) in
patients without nocturia and 28.5
(1.9) in patients without
Prevalence: NR
Galizia et al. (2012) [21] 1288 community-dwelling
individuals
Female: 57%





Mean (sd) MMSE score: 25.3 (4.8)
Prevalence: NR
Lee et al. (2012) [22] 299 community-dwelling men





Mean (sd) MMSE score: 25.6 (3.4)
Prevalence: NR
Burgio et al. (2010) [23] 1000 Medicare beneficiaries
Female: 50%





Mean (sd) MMSE score: 25 (4.9)
Prevalence (MMSE < 24): 29.8%
BPH Benign prostatic hypertrophy, CI Confidence interval, CDR Clinical Dementia Rating; DSM Diagnostic and Statistical Manual of Mental Disorders, HAMA
Hamilton Anxiety Rating Scale, HAMD Hamilton Depression Rating Scale, IPSS International Prostate Symptom Score, MoCA Montreal Cognitive Assessment, MMSE
Mini-Mental State Examination, NMSS Non-Motor Symptom Scale, NR Not reported, OABSS Overactive Bladder Symptom Score, OR Odds ratio, r Correlation
coefficient, sd Standard deviation, UPDRS Unified Parkinson’s Disease Rating Scale
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risk for bias in the measurement of exposure. Except for
one study [21], no studies published information on
blinding of outcome assessments or incomplete data. Al-
though no studies referenced a published protocol with
pre-defined outcomes, expected outcomes were reported
in the results section of all 8 studies.
Discussion
Summary of evidence
To date, only 8 cross-sectional studies involving older
populations, patients with PD, or patients with AD have
assessed the association between cognitive dysfunction
and nocturia. The overall risk of bias of these studies
was unclear. All 6 studies that identified a statistically
significant association between nocturnal voiding fre-
quency and cognitive dysfunction did so in the same dir-
ection [11, 17, 18, 21–23]. This association was shown
to be independent in 2 studies. Accordingly, current lit-
erature suggests that a lower cognitive function is associ-
ated with a higher risk of nocturia, although more
research is indeed needed to further elucidate the rela-
tionship between cognitive dysfunction and nocturia.
Although several studies have found a significant asso-
ciation between nocturia and cognitive dysfunction, the
clinical relevance of these associations must be
questioned.
Strengths and weaknesses
This systematic review is the first on the topic of cogni-
tive dysfunction and nocturia. We identified studies
which included nearly 4500 older patients in total.
However, the included study populations were hetero-
geneous, and varied in the means by which potential
confounding factors were assessed. Indeed, age, sleep
disorders, cardio-metabolic and central nervous system
diseases are the main confounding factors in the rela-
tionship between cognitive disorders and nocturia
(Fig. 3). If age is considered in each study including a
multivariable analysis, only Zhang et al. (2016) have con-
sidered sleep disorders, cardio-metabolic diseases were
partially considered in the study by Burgio et al. (2010)
Table 2 Association between cognitive dysfunction and nocturia
Study Univariate analysis Multivariable analysis
Dutoglu et al. (2019) [17] Lower MMSE scores in patients with ≥2 nocturia episodes
compared to those with < 2 episodes; MCID observed only
for the group with at least 4 nocturnal voids compared to
the group with 1 nocturnal void
No difference in dementia prevalence
Not performed
Jung et al. (2017) [11] No significant correlation between nocturia and MMSE
Significant correlation between nocturia and CDR scale:
r = 0.23; MCID: not assessable
Not performed
Zhang et al. (2016) [18] Significant difference of nocturia prevalence in patients
with cognitive dysfunction vs. without 56.3% vs. 36.8%.
Mean (sd) NMSS nocturia sub-score significantly higher
in patients with cognitive dysfunction vs. without 2.9 (3.4)
vs. 1.7 (3.0); MCID: not assessable
Urinary disorders (including nocturia) as a
significant risk factor for cognitive dysfunctiona:
OR 1.7, 95% CI [1.1–2.8]
Scullin et al. (2013) [19] No significant difference in Mean (sd) nocturia frequency
score in patients with impulsivity vs. without impulsivity
-
Vaughan et al. (2013) [20] No significant difference in MMSE score in patients with
nocturia vs. without nocturia
-
Galizia et al. (2012) [21] Mean (sd) MMSE score significantly lower in subjects with
vs. without nocturia in univariate analysis: 25.0 (5.2) vs. 25.6
(4.4); MCID not reached
Not performed
Lee et al. (2012) [22] Mean (sd) MMSE score significantly lower in subjects with
vs. without nocturia in univariate analysis: 24.4(4.0) vs.
25.9(3.4); MCID reached
Higher MMSE protective factor of nocturiab:
OR 0.6 95%CI [0.5–0.9]




BPH Benign prostatic hypertrophy; CI Confidence interval, CDR Clinical dementia rating scale (MCID: 1–2 point increase indicative of a meaningful decline), HAMA
Hamilton Anxiety Rating Scale, HAMD Hamilton Depression Rating Scale, MCID Minimal clinically important difference, MMSE Mini-Mental State Examination (MCID:
1–3 point decrease indicative of a meaningful decline), NMSS Non-Motor Symptom Scale (MCID: 13.91 point increase indicative of a meaningful change), OR Odds
ratio, r Correlation coefficient, sd standard deviation, UPDRS Unified Parkinson’s Disease Rating Scale
Variables included in multivariable analysis:
aAge, age of onset, gender, education level, scores of speech, facial expression, tremor, rigidity, bradykinesia and axial impairment in the UPDRS, total HAMD and
HAMA scores, presence of sleep/ fatigue, perceptual problems/hallucinations, attention/memory, gastrointestinal domains from NMSS
bHistory of BPH, age, education, depression, alpha-blocker, transitional zone volume of prostate
cAge, ethnicity, obesity, urban status (vs rural)
dAge, ethnicity, hypertension, lower limb oedema, history of urinary incontinence, urban status (vs rural)
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and neurological diseases were ignored if we exclude the
study in PD patients [18]. Moreover, the definition and
assessment of nocturia (e.g., self-reported voiding fre-
quency vs. symptom questionnaire data) varied across
studies, which was consistent with a previous study [25].
At the time of publication, none of the studies included
in this review used the exact terminology recommended
by the International Continence Society, which states
that each void is preceded and followed by sleep or the
intention to sleep [2, 26]. Nevertheless, several studies
used the clinically significant threshold of two or more
nocturnal voids [17, 20–23]. In addition, none of the
studies assessed nocturia on frequency volume charts,
but only on validated questionnaires or by history taking.
This may have led to a risk of misclassification bias. In-
deed, it has been shown that nocturia prevalence is
overestimated when using questionnaires [27, 28]. Mis-
estimating (over- or under-estimating) nocturnal voiding
frequency to a greater extent in patients with cognitive
dysfunction compared to those without could lead to
this bias. Regarding cognitive dysfunction, the MMSE,
was used in most of the included studies. It is a short,
patient-friendly instrument, but may be influenced by
educational attainment and age. These limitations,
coupled with the relatively small number of studies
which met the criteria for inclusion, precluded quantita-
tive synthesis of study results.
Although several studies have found a significant asso-
ciation between nocturia and cognitive dysfunction, the
clinical relevance of these associations must be ques-
tioned. While it is difficult to estimate for some studies,
it appears to have been observed in others. For example,
Fig. 2 Risk of bias in included studies. 2A. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
2B. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.?: unclear risk
of bias; −: high risk of bias; +: low risk of bias
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in the study by Lee et al. (2012), the observed difference
in MMSE between patients with nocturia and those
without nocturia was 1.5 points, which is considered
clinically significant [29].
Explanatory hypotheses
The fact that only cross-sectional studies met the criteria
for inclusion in this systematic review precludes identifi-
cation of the precise cause-and-effect relationship be-
tween cognitive dysfunction and nocturia. Nevertheless,
several non-mutually exclusive hypotheses may explain
this association (Fig. 3).
Cognitive dysfunction and nocturia share many of the
same risk factors (Part (a) of Fig. 3) including central
nervous system pathologies [30], altered circadian
rhythms of key hormones [15, 31, 32], reduction in sex
hormones [33, 34], sleep disorders [15, 34], comorbidi-
ties [13, 34], polypharmacy and modifiable lifestyle fac-
tors [13, 34, 35]. Furthermore, cognitive dysfunction
could give rise to nocturia (part (b) of Fig. 3), mainly
through impaired executive function, which is associated
with overactive bladder syndrome [11, 12], and decrease
in physical activity [36]. These two manifestations are
known causes of nocturia [3, 37]. Conversely, nocturia
could give rise to cognitive impairment (part (c) of Fig. 3).
Antimuscarinic agents use, a first-line therapy in the man-
agement of overactive bladder, may contribute to cogni-
tive dysfunction [38] through an increase of the
Fig. 3 Hypotheses for the association between cognitive dysfunction and nocturia. CNS: central nervous system; OAB: overactive bladder.
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anticholinergic load. Moreover, nocturia-induced sleep
impairment might lead to cognitive decline [13], via fac-
tors such as benzodiazepine use [15].
Conclusions
Nocturia is a complex and multifactorial condition,
which may be the result of a primary abnormality of the
genitourinary tract or a symptom of an underlying med-
ical condition. The current framework for evaluation
and management of nocturia broadly divides nocturia
into four distinct etiologies: excessive nocturnal urine
production (“nocturnal polyuria”), excessive 24-h urine
production (“global polyuria”), reduced bladder capacity
(functional or extrinsic), and sleep disorders (primary or
secondary). However, the cause-and-effect relationship
between nocturia and cognitive dysfunction remains
poorly understood, and this may fall into overlapping
pathophysiologic phenotypes. Nevertheless, the findings
from this review suggests that nocturia is associated with
cognitive impairment, and this could have consequential
impacts on clinical practice. Indeed, it could make it
possible to further appropriate assessment of signs or
symptoms of memory loss in patients with nocturia, or
to systematically look for this bothersome symptom in
patients with cognitive dysfunction.
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